Gilead Sciences Inc. announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic… read more.
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the… read more.
Alcohol-related deaths increased 18% during the pandemic, as did hospitalizations related to alcohol use, according to new research in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.241146. In the early part of the… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) (UK) has 16 January 2025, approved the medicine seladelpar (Livdelzi) in adults for the treatment of a liver illness called… read more.
Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended approval of Opdivo (nivolumab) plus Yervoy (ipilimumab) for the… read more.
A common antihistamine may offer hope for patients with a rare genetic disease that can lead to severe liver damage and ultimately require transplantation, according to new research… read more.
For the first two to three weeks of their lives, infants have to undergo screening for neonatal jaundice (NNJ). It typically involves frequent clinic visits, which is not… read more.
New research from Karolinska Institutet in Sweden highlights the potential benefits of screening people with type 2 diabetes for liver damage at the same time as they undergo… read more.
New research from Karolinska Institutet in Sweden highlights the possibility of screening people with type 2 diabetes for liver damage at the same time as they undergo screening… read more.
A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn’t… read more.
Ipsen announced late-breaking data for Iqirvo (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American… read more.
One of the main physical symptoms of alcohol withdrawal is “allodynia”— increased sensitivity to mechanical stimuli that are normally innocuous, which is a clinical sign of chronic pain…. read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
